Title : In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.

Pub. Date : 2021 May 31

PMID : 34072728






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Interestingly, NSC777201 demonstrated anti-proliferative and cytotoxic activities (GI50 = 1.6 microM~1.82 microM and TGI50 = 3.5 microM~3.63 microM) against the NCI panels of ovarian cancer cell lines and exhibited a robust interaction with stronger affinities for TTK, NEK2, and CDK1, than do the standard drug, paclitaxel. Paclitaxel cyclin dependent kinase 1 Homo sapiens